Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
MYL SLXP AKRX MNTA Tech Funds Software Large Value Education 
United States  USA  |  Optimize Portfolios


Processing
Processing. Please wait...

Salix insider: William D

       

William D - Salix Insider Profile

Chief Devel. Officer and Executive VP of RandD

We currently do not have informatin regarding William D. This executive tanure with Salix Pharmaceuticals Ltd is not currenlty determined.
Age: 51        
919-862-1000  http://www.salix.com

Management Efficency

The company has return on total asset (ROA) of 7.24 % which means that it generated profit of $7.24 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 11.57 % meaning that it created $11.57 on every $100 dollars invested by stockholders.
The company currently holds 857.26 M in liabilities with Debt to Equity (D/E) ratio of 1.53 which is about average as compared to similar companies. Salix Pharmaceuticals Ltd has Current Ratio of 4.47 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
    

Other Executives

Lorin Johnson, Founder
Carolyn Logan, CEO
Thomas DAlonzo, Chairman
William Forbes, President, Ph.D
Adam Derbyshire, CFO, MBA
Rick Scruggs, EVP
Richard Franco, Director
Mark Sirgo, Director, Ph.D
William Keane, Director, MBA
John Chappell, Director
G Freeman, Executive

Entity Summary

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals Ltd [SLXP] is traded on NASDAQ in USA. It is located in Raleigh, NC and employs 525 people. Filter other
    
Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
 
    
    
SLXP United States Nasdaq
Salix Pharmaceuticals Ltd
Currency: USD - US Dollar
Traded on NASDAQ
    
    
Chance of
Bankruptcy
Less
Than
39%
In The Next
Two Years
Salix Pharmaceuticals Ltd has less than 39.38 (%) percent chance of experiencing financial distress in the next 2 years of operations.
    
    

Salix price boundaries

    
April 19 2013
 47.76 
  
 48.46 
0.70  Macroaxis: 1.4656616415410444 Up   1.47%  
Lowest period price (30 days)
May 15 2013
 59.42 
  
 59.76 
0.34  Macroaxis: 0.5721979131605458 Up   0.57%  
Highest period price (30 days)
    

Promote Salix and William D

Follow Salix with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Salix to your reader
 

Today Change

 United States Russel   1.11 % Macroaxis: change 1.11 Moved Up  
 
 United States SP 500   1.03 % Macroaxis: change 1.03 Moved Up  
 
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States NYSE   0.92 % Macroaxis: 0.92 Moved Up  
 
 thisGreen SLXP SLXP agains markets  0.15 % Macroaxis: 0.15 Moved Up  
 

Stock Performance

Shares Outstanding61.15 M
Number of Shares Shorted2.17 M


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium